补髓生血颗粒剂对慢性再生障碍性贫血患者骨髓造血祖细胞c-kit、CXCR_4受体表达的影响  

The Influence of Blood-Engendering Granule to Bone Hematopoietic Progenitor Cell C-kit and CXCR_4 Receptor in Chronic Aplastic Anemia Patients

作　　者：孙伟正[1] 马智刚[2] 

机构地区：[1]黑龙江中医药大学附属第一医院,黑龙江哈尔滨150040 [2]黑龙江中医药大学

出　　处：《中医药学刊》2004年第6期973-974,983,共3页Study Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目 ( 3 0 2 7162 1)

摘　　要：目的 :探讨补髓生血颗粒剂对慢性再生障碍性贫血 (CAA)患者骨髓造血祖细胞c -kit、CXCR4受体表达水平的影响。方法 :采用免疫荧光法及流式细胞技术分别对使用该颗粒剂治疗前后的CAA患者骨髓造血祖细胞c-kit、CXCR4 受体表达水平进行检测 ,并与再障生血片对照组及正常组作比较研究。结果 :补髓生血颗粒剂组临床疗效与再障生血片组疗效存在显著差异(P <0 .0 5 ) ;两组疗前c -kit受体表达高于正常组 ,治疗后均表达下调 ;补髓生血颗粒剂组治疗后CXCR4 受体表达与再障生血片组存显著性差异(P <0 .0 5 )。结论 :慢性再障骨髓造血衰竭并非c -kit受体低表达所致 ;补髓生血颗粒剂在临床疗效与CXCR4 受体表达上调作用上优于再障生血片组 。To discuss the influence of blood-engendering granule to bone hematopoietic progenitor cell c-kit and CXCR 4 receptor in chornic aplastic anemia(CAA)patients.Method:Immumoflouorescence method and flow cytometer are applied to measure the pretreatment and post-treatment levels of bone hematopoietic progenitor cell c-kit and CXCR 4 receptor in CAA patients treated with blood-engendering granule,and we compare the levels with those in the controlled group treated with CAA blood-engendering tablet.Result:There is significant difference in clinical effect between blood-engendering granule group and the control group(P<0.05).The c-kit receptor expression in both of the two groups are higher than theornormal group Pretreatment and decrease post-treatment,but CXCR 4 receptor expression in blood-engendering granule guoup is notably different from that in the controlled group(P<0.05).Conclusion:CAA bone hematopoietic function failure is not due to the low expression of c-kit;blood-engendering granule is superior to CAA blood-engendering tablet in clinical effect and CXCR 4 receptor expression,and this implies blood-engendering granule stimulate hematopoiesis by increasing bone hematopoietic progenitor cell multiplication,differentiation and adhesion fuction.

关 键 词：补髓生血颗粒剂 慢性再生障碍性贫血 骨髓造血祖细胞 CXCR4受体 C-KIT受体 

分 类 号：R556.5[医药卫生—血液循环系统疾病]